Particularly, the researchers used high-throughput sequencing technologies to investigate autoimmune thyroid disease, coeliac disease, Crohn's disease, psoriasis, multiple sclerosis and Type 1 diabetes to determine new variants in 25 already identified risk genes in a sample of nearly 42,000 patients.
The results indicate that the genetic risk of these diseases rather involves a complex combination of hundreds of weak-effect variants which are each common in the population than a small number of rare variants in risk genes, as believed so far. Moreover, according to the research team, rare variants in these risk genes represent around 3% of the heritability of these conditions that can be explained by common variants.
''The results prompt a re-assessment of the genetic architecture that determines risk for development of common auto-immune disorders and will fuel future careful assessment of regions of the human genome beyond those presently known to confer susceptibility to these important medical conditions,'' said Prof. Richard Trembath, vice principal and executive dean for health at Barts and The London School of Medicine and Dentistry, Queen Mary.
Perrigo to acquire United States rights for Entocort from AstraZeneca
US FDA approves Boehringer Ingelheim's Pradaxa
Phase II clinical trial for potential treatment of androgenetic alopecia completed by Samumed
Life Sciences Partners collaborates on immuno-oncology with Bristol-Myers Squibb
Arsanis initiates first cohort in Phase one clinical trial of ASN100
Impax introduces generic Avodart (Dutasteride) Capsules, 0.5 mg
Mylan unveils generic FazaClo orally disintegrating tablets for treating schizophrenia